Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Anne Julienne Genuino, Mac Ardy Junio Gloria, Usa Chaikledkaew, Thanyanan Reungwetwattana & Ammarin Thakkinstian. (2021) Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 1001-1010.
Read now
Read now
Anne Julienne Genuino, Usa Chaikledkaew, Due Ong The, Thanyanan Reungwetwattana & Ammarin Thakkinstian. (2019) Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology 12:8, pages 815-824.
Read now
Read now
Articles from other publishers (17)
Sherif Samer Attalla, Jonathan Boucher, Hailey Proud, Tarek Taifour, Dongmei Zuo, Virginie Sanguin-Gendreau, Chen Ling, Gabriella Johnson, Vincent Li, Robin B. Luo, Hellen Kuasne, Vasilios Papavasiliou, Logan A. Walsh, Mark Barok, Heikki Joensuu, Morag Park, Philippe P. Roux & William J. Muller. (2023) HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer. Cancer Immunology Research 11:9, pages 1184-1202.
Crossref
Crossref
Alina A. Aliab'eva & Galina S. Mal. (2021) Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases. CardioSomatics 12:3, pages 177-181.
Crossref
Crossref
Siao-Nge Hoon, Peter K H Lau, Alison M White, Max K Bulsara, Patricia D Banks & Andrew D Redfern. (2021) Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database of Systematic Reviews 2021:5.
Crossref
Crossref
Johanna Alanko, Minna Tanner, Ritva Vanninen, Anssi Auvinen & Jorma Isola. (2021) Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Research and Treatment 187:1, pages 267-274.
Crossref
Crossref
Meiying Shen, Huawen Pan, Yuxia Chen, Yu Hang Xu, Weixiong Yang & Zhaojun Wu. (2020) A review of current progress in triple-negative breast cancer therapy. Open Medicine 15:1, pages 1143-1149.
Crossref
Crossref
Karama Asleh, Heather Ann Brauer, Amy Sullivan, Susanna Lauttia, Henrik Lindman, Torsten O. Nielsen, Heikki Joensuu, E. Aubrey Thompson & Saranya Chumsri. (2020) Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. Clinical Cancer Research 26:11, pages 2603-2614.
Crossref
Crossref
Yan Li, Yidong Zhou, Feng Mao, Yan Lin, Xiaohui Zhang, Songjie Shen & Qiang Sun. (2019) Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Breast Cancer Research and Treatment 179:3, pages 533-542.
Crossref
Crossref
Anne Julienne Genuino, Usa Chaikledkaew, Anna Melissa Guerrero, Thanyanan Reungwetwattana & Ammarin Thakkinstian. (2019) Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Services Research 19:1.
Crossref
Crossref
Florence R. Wilson, Megan E. Coombes, Christine Brezden-Masley, Mariya Yurchenko, Quinlan Wylie, Reuben Douma, Abhishek Varu, Brian Hutton, Becky Skidmore & Chris Cameron. (2018) Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Systematic Reviews 7:1.
Crossref
Crossref
Gelareh Farshid & David Walters. (2018) Molecular subtypes of screen-detected breast cancer. Breast Cancer Research and Treatment 172:1, pages 191-199.
Crossref
Crossref
Qibing Zhang, Xiaojun Shan, Yu Fu, Pengyu Liu, Xiaofeng Li, Baocui Liu, Lijun Zhang & Dong Li. (2017) Electrochemical Determination of the Anticancer Drug Capecitabine Based on a Graphene-Gold Nanocomposite-Modified Glassy Carbon Electrode. International Journal of Electrochemical Science 12:11, pages 10773-10782.
Crossref
Crossref
Karen A. Cadoo, Patrick G. Morris, Elizabeth P. Cowell, Sujata Patil, Clifford A. Hudis & Heather L. McArthur. (2016) Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer 16:6, pages 487-493.
Crossref
Crossref
Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin & Xu-Yuan Li. (2016) Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. PLOS ONE 11:10, pages e0164663.
Crossref
Crossref
Hui-Dong Long, Yun-En Lin, Juan-Juan Zhang, Wen-Zhao Zhong & Rui-Nian Zheng. (2016) Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis. The Oncologist 21:5, pages 547-554.
Crossref
Crossref
Charla C. Engels, Mandy Kiderlen, Esther Bastiaannet, Ronald van Eijk, Antien Mooyaart, Vincent T. H. B. M. Smit, Anton J. M. de Craen, Peter J. K. Kuppen, Judith R. Kroep, Cornelis J. H. van de Velde & Gerrit Jan Liefers. (2016) The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis. Breast Cancer Research and Treatment 156:2, pages 361-370.
Crossref
Crossref
Yong SunTao LiYuanpeng ZhangQiwen Zhang. (2016) Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment. Medical Science Monitor 22, pages 5035-5040.
Crossref
Crossref
Adedayo A. Onitilo, Jessica M. Engel & Rachel V. Stankowski. (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Therapeutic Advances in Drug Safety 5:4, pages 154-166.
Crossref
Crossref